» Articles » PMID: 24130003

Comparable Performance of the Kansas City Cardiomyopathy Questionnaire in Patients with Heart Failure with Preserved and Reduced Ejection Fraction

Overview
Journal Circ Heart Fail
Date 2013 Oct 17
PMID 24130003
Citations 82
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Despite the growing epidemic of heart failure with preserved ejection fraction (HFpEF), no valid measure of patients' health status (symptoms, function, and quality of life) exists. We evaluated the Kansas City Cardiomyopathy Questionnaire (KCCQ), a validated measure of HF with reduced EF, in patients with HFpEF.

Methods And Results: Using a prospective HF registry, we dichotomized patients into HF with reduced EF (EF≤ 40) and HFpEF (EF≥50). The associations between New York Heart Association class, a commonly used criterion standard, and KCCQ Overall Summary and Total Symptom domains were evaluated using Spearman correlations and 2-way ANOVA with differences between patients with HF with reduced EF and HFpEF tested with interaction terms. Predictive validity of the KCCQ Overall Summary scores was assessed with Kaplan-Meier curves for death and all-cause hospitalization. Covariate adjustment was made using Cox proportional hazards models. Internal reliability was assessed with Cronbach's α. Among 849 patients, 200 (24%) had HFpEF. KCCQ summary scores were strongly associated with New York Heart Association class in both patients with HFpEF (r=-0.62; P<0.001) and HF with reduced EF (r=-0.55; P=0.27 for interaction). One-year event-free rates by KCCQ category among patients with HFpEF were 0 to 25=13.8%, 26 to 50=59.1%, 51 to 75=73.8%, and 76 to 100=77.8% (log rank P<0.001), with no significant interaction by EF (P=0.37). The KCCQ domains demonstrated high internal consistency among patients with HFpEF (Cronbach's α=0.96 for overall summary and ≥0.69 in all subdomains).

Conclusions: Among patients with HFpEF, the KCCQ seems to be a valid and reliable measure of health status and offers excellent prognostic ability. Future studies should extend and replicate our findings, including the establishment of its responsiveness to clinical change.

Citing Articles

Cardiopulmonary exercise capacity markers and their link to symptom burden in patients at risk for heart failure with non-reduced ejection fraction.

Kwast S, Hoffmann J, Pokel C, Falz R, Schulze A, Schroter T Sci Rep. 2025; 15(1):8940.

PMID: 40089637 DOI: 10.1038/s41598-025-94172-1.


Macitentan for Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Pulmonary Vascular Disease: Results of the SERENADE Randomized Clinical Trial and Open-Label Extension Study.

Shah S, Bonderman D, Borlaug B, Cleland J, Lack G, Lu W Circ Heart Fail. 2025; :e011381.

PMID: 40066571 PMC: 11905905. DOI: 10.1161/CIRCHEARTFAILURE.123.011381.


Defining patient-reported outcomes in diabetes, obesity, cardiovascular disease, and chronic kidney disease for clinical practice guidelines - perspectives of the taskforce of the Guideline Workshop.

Barnard-Kelly K, Battelino T, Brosius F, Ceriello A, Cosentino F, Gavin 3rd J Cardiovasc Diabetol. 2025; 24(1):68.

PMID: 39920737 PMC: 11806799. DOI: 10.1186/s12933-024-02550-2.


Left Ventricular Assist Device in Advanced Refractory Heart Failure: A Comprehensive Review of Patient Selection, Surgical Approaches, Complications and Future Perspectives.

Al Hazzouri A, Attieh P, Sleiman C, Hamdan R, Ghadieh H, Harbieh B Diagnostics (Basel). 2024; 14(22).

PMID: 39594146 PMC: 11593065. DOI: 10.3390/diagnostics14222480.


Interpreting Population Mean Treatment Effects in the Kansas City Cardiomyopathy Questionnaire: A Patient-Level Meta-Analysis.

Abdel Jawad M, Jones P, Arnold S, Cohen D, Sherrod C, Khan M JAMA Cardiol. 2024; 10(1):32-40.

PMID: 39546393 PMC: 11841199. DOI: 10.1001/jamacardio.2024.4470.


References
1.
Borlaug B, Redfield M . Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation. 2011; 123(18):2006-13. PMC: 3420141. DOI: 10.1161/CIRCULATIONAHA.110.954388. View

2.
Kosiborod M, Soto G, Jones P, Krumholz H, Weintraub W, Deedwania P . Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments. Circulation. 2007; 115(15):1975-81. DOI: 10.1161/CIRCULATIONAHA.106.670901. View

3.
Arnold S, Spertus J, Jones P, Xiao L, Cohen D . The impact of dyspnea on health-related quality of life in patients with coronary artery disease: results from the PREMIER registry. Am Heart J. 2009; 157(6):1042-9.e1. DOI: 10.1016/j.ahj.2009.03.021. View

4.
McLeod L, Coon C, Martin S, Fehnel S, Hays R . Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011; 11(2):163-9. PMC: 3125671. DOI: 10.1586/erp.11.12. View

5.
OMeara E, Lewis E, Granger C, Dunlap M, McKelvie R, Probstfield J . Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur J Heart Fail. 2005; 7(4):650-6. DOI: 10.1016/j.ejheart.2005.01.021. View